An interventional study of Artificial Tears (AT) and 20/20/20 rule in Dry Eye, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Zagazig University · Not applicable, Interventional, and Treatment
Among 24 studies in Dry Eye Syndromes with a site in Egypt — 6 open to participants now, 7 under way, none of them phase 3. Dry Eye Syndromes · Egypt.
Among the 24 studies in Dry Eye Syndromes with a site in Egypt, this one is the 10th largest by enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2025, is one of 12 with no phase, and was the 24th registered.
1,367 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →6 of the 24 studies in Dry Eye Syndromes with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 30–40 · Women only
The General Authority for Teaching Hospitals and Institutes · Sites in Egypt
Ages up to 18
Ace Cells Lab Limited · Sites in Egypt
Ages 18–80
Cairo University · Sites in Egypt
Ages 45–55
Sohag University · Sites in Egypt
Ages 45+ · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 50 across the 17 interventional studies, 100 across the 7 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 24 have an industry lead sponsor. The 10 most frequent:
Zagazig University is the lead sponsor of 459 studies on the registry; 77 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Zagazig University has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Dry Eye Syndromes with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is for anyone struggling with dry, tired, or uncomfortable eyes, especially from long hours on screens.
Investigators all know that feeling after staring at a laptop or phone too long. This study from Zagazig University looks at a simple habit called the 20-20-20 rule: every 20 minutes, take a 20-second break to look at something about 20 feet away. Investigators want to see if doing this every day, along with participant's regular artificial tears, helps participants eyes feel better than tears alone.
If participant join, participant will use artificial tears as usual. Some participants will also be asked to practice the 20-20-20 rule throughout the day. Investigators will follow participant for about 8 weeks and check participant symptoms, tear film, and overall eye comfort with simple eye exams and questionnaires.
There is no experimental drug involved, just a daily habit Investigators hope will make standard treatment work better. The study was approved by the Institutional Review Board, Faculty of Medicine, Zagazig University on 07-September-2024.
*Intervention:*
Group B (Experimental, n=24): Same artificial tears (same dose/duration) + 20-20-20 rule instructions throughout the workday, reinforced via eye-blink reminder application for 3 months.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Inclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\*Arm 1 Description:\* Preservative-free artificial tears (sodium hyaluronate), 1 drop in each affected eye 4 times daily for 3 months. No 20-20-20 rule intervention.
Drug: Artificial Tears (AT)
\*Arm 2 Description:\* Same artificial tears regimen as Arm 1 (1 drop in each affected eye 4 times daily for 3 months) PLUS the 20-20-20 rule (every 20 minutes, look at something 20 feet away for 20 seconds), reinforced by an eye-blink reminder application during work hours for 3 months.
Drug: Artificial Tears (AT) · Behavioral: 20/20/20 rule
1\. Artificial Tears (Drug): for arm 1 Preservative-free sodium hyaluronate ophthalmic solution, 1 drop in each eye 4 times daily for 3 months. Standard lubricating therapy for video display terminal-associated dry eye, given to both arms as background treatment.
Participants are instructed to follow the 20-20-20 rule during all video display terminal use: every 20 minutes of continuous screen work, look at an object at least 20 feet (6 meters) away for at least 20 seconds, accompanied by 5 conscious, complete blinks. To reinforce adherence, participants install an eye-blink reminder application on their phone/work computer that prompts every 20 minutes during work hours. Training on the rule is provided at baseline with a written leaflet. Duration: throughout the 3-month study period, during work hours (approx. 8 hours/day).
Change in Ocular Surface Disease Index (OSDI) score from baseline to 3 months.
OSDI is a 12-item validated questionnaire scored 0-100, with higher scores indicating more severe symptoms.
Time frame: Assessed at baseline, 6 weeks, and 3 months
Change in Non-Invasive Keratograph Break-Up Time (NIKBUT)
First and average NIKBUT in seconds, measured automatically by the Dry Eye Analyzer.
Time frame: Assessed at baseline, 6 weeks, and 3 months.
Change in Central Lower Tear Meniscus Height (TMH)
Central lower tear meniscus height in mm, measured by the Dry Eye Analyzer.
Time frame: Assessed at baseline, 6 weeks, and 3 months.
Change in Bulbar Conjunctival Redness Score
Objective bulbar redness graded 0-4 by the analyzer's automated R-scan.
Time frame: Assessed at baseline, 6 weeks, and 3 months.
Change in Meibomian Gland Loss
Percentage of meibomian gland loss in upper and lower eyelids assessed by infrared meibography using the analyzer.
Time frame: Assessed at baseline, 6 weeks and 3 months
Plan to share: Yes — De-identified Individual Participant Data (IPD) for all 48 participants will be shared, including:Demographics: Age, Sex, Occupation (IT employee)Treatment Assignment: Group A (Preservative-free artificial tears 4x daily) vs Group B (Same artificial tears + 20-20-20 rule with reminder app)Visit Data at Baseline, First Follow-up (1 month), and Second Follow-up (3 months):Ocular Surface Disease Index (OSDI) scoreNon-invasive tear break-up time (NIBUT) (seconds)Tear Meniscus Height (TMH) (mm)Lipid layer assessmentBulbar redness scanMeibomian gland opening (Normal/Mild/Moderate)Meibomian gland dysfunction (MGD) score (0/1/2)Data will be provided as a de-identified participant-level dataset with a data dictionary, along with the Study Protocol and Statistical Analysis Plan.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 3 months and ending 5 years after publication
Access criteria: Who can access: De-identified IPD and supporting documents will be made available to qualified researchers, academic institutions, and healthcare professionals who submit a scientifically sound proposal.What can be accessed: De-identified individual participant-level dataset for the 48 participants (48 eyes), including demographics, treatment assignment, OSDI scores, Dry Eye Analyzer parameters (NIBUT, TMH, lipid layer, red scan, meibomian gland opening, MGD) at baseline and follow-ups, plus the Study Protocol, Statistical Analysis Plan, and Informed Consent Form with Data Dictionary. No identifiable personal information will be shared.How to access: Requests should be sent to the Corresponding Author, Lillian Samir Salama Srour, Ophthalmology Department, Faculty of Medicine, Zagazig University, Egypt, via the faculty contact http://en.medicine.zu.edu.eg/faculty/default. Requests must include a study proposal and analysis plan. Upon approval by the study team and Zagazig University IRB
Data sharing details ↗ · en.medicine.zu.edu.eg
Ran from Sep 2025 to primary completion in Mar 2026, 6 months.
Of 199 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's 6 months is below that.
Counting every sponsor, half of 312 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.